BD and Biocorp joined forces to improve the outcomes and adherence of self-administered drugs through connected drug delivery, by combining the use of digital technology with prefillable syringes.
Key insights:
- BD and Biocorp have signed an agreement to integrate the use of digital technology with self-administered therapies, via connected drug delivery.
- This type of connected drug delivery captures and transmits self-administered injection data, to help improve patient experience, adherence and experience.
- With NFC technology, information can easily be transferred from the complete injection to a smartphone through specific sensors.
The global market of connected drug delivery is expected to hit double-digit growth rates over the next decade – fueled by the transition from acute healthcare to home care, and the increased prevalence of self-administered therapies.